196 related articles for article (PubMed ID: 15725837)
1. Halofuginone inhibits collagen deposition in fibrous capsules around implants.
Olbrich KC; Meade R; Bruno W; Heller L; Klitzman B; Levin LS
Ann Plast Surg; 2005 Mar; 54(3):293-6;discussion 296. PubMed ID: 15725837
[TBL] [Abstract][Full Text] [Related]
2. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury.
Ozçelik MF; Pekmezci S; Saribeyoğlu K; Unal E; Gümüştaş K; Doğusoy G
Am J Surg; 2004 Feb; 187(2):257-60. PubMed ID: 14769315
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
4. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis.
Karatas A; Paksoy M; Erzin Y; Carkman S; Gonenc M; Ayan F; Aydogan F; Uzun H; Durak H
J Surg Res; 2008 Jul; 148(1):7-12. PubMed ID: 18570924
[TBL] [Abstract][Full Text] [Related]
5. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M
J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768
[TBL] [Abstract][Full Text] [Related]
6. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
McGaha TL; Phelps RG; Spiera H; Bona C
J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
[TBL] [Abstract][Full Text] [Related]
7. Surface modification of silicone breast implants by binding the antifibrotic drug halofuginone reduces capsular fibrosis.
Zeplin PH; Larena-Avellaneda A; Schmidt K
Plast Reconstr Surg; 2010 Jul; 126(1):266-274. PubMed ID: 20595874
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone prevents extracellular matrix deposition in diabetic nephropathy.
Sato S; Kawamura H; Takemoto M; Maezawa Y; Fujimoto M; Shimoyama T; Koshizaka M; Tsurutani Y; Watanabe A; Ueda S; Halevi K; Saito Y; Yokote K
Biochem Biophys Res Commun; 2009 Feb; 379(2):411-6. PubMed ID: 19114027
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of prostate cancer xenografts by halofuginone.
Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
[TBL] [Abstract][Full Text] [Related]
11. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats.
Spira G; Mawasi N; Paizi M; Anbinder N; Genina O; Alexiev R; Pines M
J Hepatol; 2002 Sep; 37(3):331-9. PubMed ID: 12175628
[TBL] [Abstract][Full Text] [Related]
12. The use of halofuginone in limiting urethral stricture formation and recurrence: an experimental study in rabbits.
Jaidane M; Ali-El-Dein B; Ounaies A; Hafez AT; Mohsen T; Bazeed M
J Urol; 2003 Nov; 170(5):2049-52. PubMed ID: 14532851
[TBL] [Abstract][Full Text] [Related]
13. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of topically applied halofuginone in management of subglottic stenosis in rats.
Ertuğrul EE; Cekin IE; Cincik H; Doğru S; Güngör A
Otolaryngol Head Neck Surg; 2009 May; 140(5):720-3. PubMed ID: 19393418
[TBL] [Abstract][Full Text] [Related]
15. Biocompatibility of steroid-HA delivery system using adult castrated rams as a model.
Benghuzzi H; England B
Biomed Sci Instrum; 2001; 37():275-80. PubMed ID: 11347402
[TBL] [Abstract][Full Text] [Related]
16. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
[TBL] [Abstract][Full Text] [Related]
17. Halofuginone inhibits serum-stimulated pericardial tissue retraction in vitro.
Marchion DC; Weber PA; Lomnitski L; Duran CM; Cheung DT
Tissue Eng; 2004; 10(7-8):1076-83. PubMed ID: 15363165
[TBL] [Abstract][Full Text] [Related]
18. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
Pines M; Knopov V; Genina O; Lavelin I; Nagler A
J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
[TBL] [Abstract][Full Text] [Related]
19. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes.
Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Abu-Amara SN; Geiger B; Genina O; Monsonego-Ornan E; Pines M
J Hepatol; 2004 Feb; 40(2):269-77. PubMed ID: 14739098
[TBL] [Abstract][Full Text] [Related]
20. The effect of liposome-delivered prednisolone on collagen density, myofibroblasts, and fibrous capsule thickness around silicone breast implants in rats.
Moreira M; Fagundes DJ; de Jesus Simões M; Taha MO; Perez LM; Bazotte RB
Wound Repair Regen; 2010; 18(4):417-25. PubMed ID: 20636553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
